Document is current
Any future updates will be listed below
-
Authors
Traxler, Juliane https://orcid.org/0000-0002-5995-1025
da Silva Burger, Neuza https://orcid.org/0000-0003-4110-9961
Augustin, Matthias https://orcid.org/0000-0002-4026-8728
Ott, Hagen https://orcid.org/0000-0003-1792-3947
Hoffmann, Sanna
Fölster-Holst, Regina
Baumeister, Maria
Staubach, Petra https://orcid.org/0000-0002-2276-0284
Sommer, Rachel https://orcid.org/0000-0002-3080-497X
-
Funding
Funding for this research was provided by:
Eli Lilly Germany
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 26 June 2025
Revised: 17 September 2025
Accepted: 19 September 2025
First Online: 20 October 2025
Declarations
:
: This study was performed in compliance with the Helsinki Declaration and approved by the ethics committee of the University Medical Center Hamburg-Eppendorf (date: 20.04.2021; reference: LPEK-0304).
: Informed consent was obtained from all participants.
: Financial interests: JT, NdSB, HO, SH, RF-H, MB, and RS declare they have no financial interests. MA has served as a consultant, lecturer, researcher, and has received institutional research grants from companies manufacturing drugs for skin diseases in children, including Eli Lilly and others. PS has served as a consultant, lecturer, and researcher and has received institutional research grants from companies manufacturing drugs for skin diseases in children, including Eli Lilly and others. Non-financial interests: none.
